BRCA Testing and PARPi in EBC

CE / CME

BRCA Testing and the Role of PARP Inhibition in Early Breast Cancer: A Multidisciplinary Roundtable

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 27, 2023

Expiration: March 26, 2024

Activity

Progress
1
Course Completed
References 

  1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
  2. Hasson SP, Menes T, Sonnenblick A. Comparison of patient susceptibility genes across breast cancer: implications for prognosis and therapeutic outcomes. Pharmgenomics Pers Med. 2020;13:227-238.
  3. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38:1346-1366.
  4. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105-2122.
  5. Albarracin C, Dhamne S. Ki67 as a Biomarker of prognosis and prediction: is it ready for use in routine pathology practice? Curr Breast Cancer Rep. 2014;6:260-266.
  6. Nielsen TO, Leung SC, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113:808-819.
  7. Mersereau M, Chen H, Albarracin C. Ki67 quantitation in breast cancer: a comparative analysis of four counting methodologies. openworks.mdanderson.org/sumexp22/92. Accessed January 17, 2023.
  8. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.
  9. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
  10. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558-566.
  11. Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526-1535.
  12. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca; 2018.
  13. Talazoparib [prescribing information]. New York, NY: Pfizer; 2018.
  14. Tutt ANJ, Garber J, Kaufman G, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
  15. Zelnak AB, O’Regan RM. Genomic subtypes in choosing adjuvant therapy for breast cancer. Oncology (Williston Park). 2013;27:204-210.
  16. Tutt A, Garber JE, Kaufman B, et al. OlympiA: a phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Presented at: 2021 ASCO Annual Meeting, June 4-8, 2021. Abstract LBA1.
  17. Tutt ANJ, Garber J, Gelber, et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Presented at: 2022 ESMO Annual Conference; September 9-13, 2022. Abstract VP1-2022.
  18. Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  19. Ganz PA, Bandos H, Spanic T, et al. Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer. Presented at: 2021 SABCS; December 7-10, 2021. Abstract GS4-09.
  20. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic. v.2.2023. nccn.org. Accessed January 17, 2023.
  21. Tung NM, Zakalik D, Somerfield MR, et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. J Clin Oncol. 2021;39:2959-2961.
  22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.4.2022. nccn.org. Accessed January 17, 2023.
  23. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guideline on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26:3025-3031.
  24. Yadav S, Reeves A, Campian S, et al. Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis. Hered Cancer Clin Pract. 2017;15:11.
  25. Park S, Lee JE, Ryu JM, et al. Genetic diagnosis before surgery has an impact on surgical decision in BRCA mutation carriers with breast cancer. World J Surg. 2018;42:1384-1390.
  26. Weitzel JN, McCaffrey SM, Nedelcu R, et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138:1323-1328.
  27. Dettwyler SA, Thull DL, McAuliffe PF, et al. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy. Breast Cancer Res Treat. 2022;194:393-401.
  28. Vargason AB, Turner CE, Shriver CD, et al. Influence of germline test results on surgical decision making in women with invasive breast cancer. Cancer Genet. 2022;266-267:81-85.
  29. Lokich E, Stuckey A, Raker C, et al. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134:326-330.
  30. Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29:1956-1962.
  31. Hortobagyi GN, Connolly JL, D’Orsi CJ, et al. Breast. In: Amin MB, Edge S, Greene F, et al, editors; American Joint Committee on Cancer. AJCC Cancer Staging Manual, 8th Edition. New York, NY: Springer; 2017.
  32. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
  33. Gumaste PV, Penn LA, Cymerman RM, et al. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol. 2015;172:1498-1506.
  34. Loap P, Loirat D, Berger F, et al. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase I olaparib and radiation therapy for triple-negative breast cancer trial. JAMA Oncol. 2022;8:1802-1808.
  35. Evans TRJ, Eatock MM, Lewsley L-A, et al. A phase I study of olaparib in combination with capecitabine-based chemoradiation (CR) in patients (pts) with locally advanced pancreatic cancer (LAPC). Presented at: 2020 ASCO Annual Meeting; May 29-31, 2020. Abstract 709.
  36. Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.
  37. Domcheck SM, Postel-Vinay S, Im S-A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155-1164.
  38. Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141-1149.
  39. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
  40. van Mackelenbergh, Seither F, Möbus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy: a meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. Eur J Cancer. 2022;166:185-201.
  41. Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020;38:203-213.
  42. Mayer IA, Zhao F, Arteaga CL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021;39:2539-2551.
  43. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  44. Johnston S, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. Presented at: 2022 SABCS; December 6-10, 2022. Abstract GS1-09.
  45. Johnston S, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77-90.
  46. Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-The Penelope-B Trial. J Clin Oncol. 2021;39:1518-1530.
  47. Safonov A, Bandlamudi C, Tallon de Lara P, et al. Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance. Presented at: 2021 SABCS; December 7-10, 2021. Abstract GS4-08.
  48. Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38:4274-4282.
  49. Gruber JJ, Afghahi A, Timmes K, et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer. 2022;3:1181-1191.